Alligator Bioscience AB (FRA:7AL0) Research & Development: €0.00 Mil (TTM As of Mar. 2026)


FRA:7AL0 Alligator Bioscience AB FRA:7AL0
39 GF Score
Price €0.00
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB Research & Development?

Alligator Bioscience AB FRA:7AL0 39 Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:7AL0 with a GF Score™ of 39/100. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Alligator Bioscience AB's Research & Development for the three months ended in Mar. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Alligator Bioscience AB  (FRA:7AL0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alligator Bioscience AB Research & Development Related Terms

Alligator Bioscience AB Research & Development Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB Research & Development Chart

Alligator Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.62 12.27 18.18 13.31 6.20

Alligator Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:7AL0
39GF Score
Alligator Bioscience AB FRA:7AL0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alligator Bioscience AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Alligator Bioscience AB (FRA:7AL0) has a Research & Development of €0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Alligator Bioscience AB and its competitors.
Is Alligator Bioscience AB's Research & Development too high?
Alligator Bioscience AB's current Research & Development is €0.00 Mil. Overall, Alligator Bioscience AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's Research & Development compare to VRTX and REGN?
Alligator Bioscience AB's Research & Development of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current Research & Development of €0.00 Mil. The current Research & Development is €0.00 Mil. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden0RK9:UK
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score

Get the complete analysis for FRA:7AL0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price